MultiOmic Health presents at LSX Investival 2024
Watch our CEO Robert Thong talk about how we are advancing precision medicine for metabolic-syndrome-related conditions at the LSX Investival Showcase in London.
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease
MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
A paper by the MultiOmic team members was published in the May issue of the ICT magazine
What insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?